- Home
- NVGS vs AVBP Comparison
NVGS vs AVBP Comparison
Compare NVGS & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- AVBP
- Stock Information
- Founded
- NVGS 1997
- AVBP 2021
- Country
- NVGS United Kingdom
- AVBP United States
- Employees
- NVGS N/A
- AVBP N/A
- Industry
- NVGS Marine Transportation
- AVBP
- Sector
- NVGS Consumer Discretionary
- AVBP
- Exchange
- NVGS Nasdaq
- AVBP NYSE
- Market Cap
- NVGS 957.8M
- AVBP 617.4M
- IPO Year
- NVGS N/A
- AVBP 2024
- Fundamental
- Price
- NVGS $13.40
- AVBP $18.95
- Analyst Decision
- NVGS Strong Buy
- AVBP Strong Buy
- Analyst Count
- NVGS 3
- AVBP 6
- Target Price
- NVGS $22.00
- AVBP $39.00
- AVG Volume (30 Days)
- NVGS 282.6K
- AVBP 187.1K
- Earning Date
- NVGS 03-12-2025
- AVBP 03-03-2025
- Dividend Yield
- NVGS 1.50%
- AVBP N/A
- EPS Growth
- NVGS 8.18
- AVBP N/A
- EPS
- NVGS 1.19
- AVBP N/A
- Revenue
- NVGS $566,679,000.00
- AVBP N/A
- Revenue This Year
- NVGS $3.48
- AVBP $63.13
- Revenue Next Year
- NVGS $1.14
- AVBP N/A
- P/E Ratio
- NVGS $11.25
- AVBP N/A
- Revenue Growth
- NVGS 2.90
- AVBP N/A
- 52 Week Low
- NVGS $13.25
- AVBP $14.35
- 52 Week High
- NVGS $18.18
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- NVGS 28.18
- AVBP 31.12
- Support Level
- NVGS $13.88
- AVBP $17.89
- Resistance Level
- NVGS $14.47
- AVBP $20.59
- Average True Range (ATR)
- NVGS 0.45
- AVBP 1.05
- MACD
- NVGS 0.01
- AVBP -0.05
- Stochastic Oscillator
- NVGS 11.90
- AVBP 21.83
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.